Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Win For Sofosbuvir In India But "Tortured" Ruling Faces Appeal

Executive Summary

India has approved a Gilead Sciences Inc. patent that claims the active metabolites of sofosbuvir amid allegations by opponents of "external pressures" on the patent office and that the decision "weakens" Section 3(d) of India's patent regulation.

You may also be interested in...

Court points to 'para lifts', potential for bias in Indian Sovaldi case

A recent Delhi High Court order that set aside the rejection of one of Gilead's key patent applications for its hepatitis C treatment, Sovaldi (sofosbuvir), in India has made some seemingly embarrassing observations on how the patent office may have been potentially ''influenced'' by material placed on record by pre-grant opposition applicants.

Cut price generics in sight as Gilead licenses Sovaldi

Sovaldi (sofosbuvir) licensee Cipla intends to keep a ''very keen eye'' on the product's affordability and hopes, going forward, to pare prices below Gilead Sciences' reported $900 offer in Egypt for a course of treatment with the product.

Novartis sees India Glivec ruling indicative of IP 'de-recognition'

India's Supreme Court has dismissed with costs Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law (, 1 April 2013).





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts